Results 101 to 110 of about 11,492 (188)

A real-world pharmacovigilance study of omalizumab using disproportionality analysis in the FDA adverse drug events reporting system database

Scientific Reports
Omalizumab is a biologic agent used in the management of allergic conditions, including asthma and urticaria. Although the efficacy of omalizumab has been well established, its safety profile is primarily derived from clinical trials with limited sample ...
Yongfu Song, Zhuang Wang, Na Wang, Xiaofei Xie, Tieshi Zhu, Yongji Wang   +5 more
doaj   +1 more source

Induced sputum versus exhaled nitric oxide for the evaluation of airway inflammation in allergic paediatric asthma patients treated with omalizumab [PDF]

, 2013
Our purpose is to determine the inflammatory changes in the airways of allergic paediatric asthma patients treated with omalizumab, measured by the percentage ofEl nostre objectiu és determinar els canvis inflamatoris en la via aèria de pacients ...
Domingo Miró, Xavier, Universitat Autònoma de Barcelona. Departament de Medicina, Universitat Autònoma de Barcelona. Facultat de Medicina   +2 more
core   +1 more source

Algorithms in Allergy: Hereditary Angioedema

Allergy, EarlyView.
Konrad Bork, Markus Magerl, Emel Aygören‐Pürsün, Henriette Farkas   +3 more
wiley   +1 more source

Incidence, severity and potential pathomechanism of immune‐related pruritus in melanoma patients undergoing immune checkpoint inhibitor therapy

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives Pruritus is a frequent cutaneous immune‐related adverse event (irAE) associated with immune checkpoint inhibitors (ICI), impacting patients' quality of life. This study investigates the incidence, severity and management of pruritus in melanoma patients treated with ICI.
Andrea Roggo, Nikolina Ivanovic, Patrick Turko, Lukas Kraehenbuehl, Mitchell Levesque, Reinhard Dummer, Barbara Meier‐Schiesser   +6 more
wiley   +1 more source

Allosteric mechanism of action of the therapeutic anti-IgE antibody omalizumab [PDF]

, 2017
Immunoglobulin E and its interactions with receptors FcϵRI and CD23 play a central role in allergic disease. Omalizumab, a clinically approved therapeutic antibody, inhibits the interaction between IgE and FcϵRI, preventing mast cell and basophil ...
Allan, EG, Beavil, AJ, Ceska, T, Cossins, BP, Craggs, G, Davies, AM, Delgado, J, Henry, AJ, Keeble, AH, McDonnell, JM, Mitropoulou, AN, Pang, MOY, Sutton, BJ, Westwood, M   +13 more
core  

A Pharmaco-Economic Analyzis of Treating Severe Uncontrolled Child Asthma with Omalizumab — Actual Russian Clinical Practice Data

Педиатрическая фармакология, 2016
Background: Omalizumab is the first and yet the only biopreparation for asthma which combines high efficiency and high cost. The clinical-economic expediency of using omalizumab in asthmatic children has not been previously studied in Russia.Objective ...
A. S. Kolbin, L. S. Namazova-Baranova, E. A. Vishneva, M. Y. Frolov, T. L. Galankin, A. A. Alekseeva, E. A. Dobrynina   +6 more
doaj   +1 more source

Omalizumab is Effective and Safe in the Treatment of Japanese Cedar Pollen-induced Seasonal Allergic Rhinitis

Allergology International, 2006
Background: Seasonal allergic rhinitis (SAR) induced by Japanese cedar pollen is a substantial problem in Japan. Omalizumab, a novel humanized monoclonal anti-immunoglobulin E (IgE) antibody, has already been proven to reduce symptoms associated with SAR.
Kimihiro Okubo, Satoshi Ogino, Toshikazu Nagakura, Takeru Ishikawa   +3 more
doaj   +1 more source

Isolated Mast Cell–Mediated Angioedema: Clinically Different but Endotypically Similar to Chronic Spontaneous Urticaria

Clinical &Experimental Allergy, EarlyView.
Thomas Buttgereit, Claudia Hayford, Carolina Vera Ayala, Sherezade Moñino‐Romero, Yi‐Kui Xiang, Pavel Kolkhir, Carolin Steinert, Denise Freier, Markus Magerl, Jörg Scheffel, Karsten Weller   +10 more
wiley   +1 more source

CH50 as a Clinically Useful Biomarker of Disease Activity and Antihistamine Resistance in Chronic Spontaneous Urticaria: An Observational Ambispective Single‐Center Study

International Journal of Dermatology, EarlyView.
Personalized CSU care guided by CH50. ABSTRACT Background Chronic spontaneous urticaria (CSU) is frequently refractory to guideline‐based therapy, highlighting the need for predictive biomarkers. Dysregulation of the complement system has been implicated in CSU severity, but global complement activity has not been systematically evaluated.
Nidia Planella‐Fontanillas, Emilio Berna‐Rico, David Pesqué, Evelyn Andrades, Silvia Sánchez, Paloma Torres‐Bosó, Ramon Gimeno, Fernando Gallardo, Ramon M. Pujol, Ana M. Giménez‐Arnau   +9 more
wiley   +1 more source

Family quality‐of‐life burden in chronic spontaneous urticaria: A multicentre study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Poor control of chronic spontaneous urticaria (CSU) significantly worsens family members' quality of life, especially in emotional, physical, and social domains. Higher disease severity was linked to increased caregiving burden and household expenditures, highlighting the need for family‐centred CSU care and support across diverse global populations ...
Beatrice Martinez Zugaib Abdalla, Roberta Fachini Jardim Criado, Kanokvalai Kulthanan, Emek Kocatürk, Ivan Cherrez‐Ojeda, Ana Maria Giménez‐Arnau, Marcus Maurer, Luis Felipe Ensina, Jonathan A. Bernstein, Michihiro Hide, Sergio Duarte Dortas Junior, Solange Oliveira Rodrigues Valle, Gabriela Dias, Paraskevi Xepapadak, Priyanshi Dangi, Indrashis Podder, Vesna Trajkova, Natasa Teovska Mitrevska, Iman Hamed Nasr, Bushra Al Hinai, Joanna Bartosińska, Dorota Krasowska, Paulina Szczepanik‐Kułak, Hilal Gungor, Deniz Ozceker, Kübra Çiçek, Esen Özkaya, Yasemin Erdem, Mücahit Ergün, Mustafa Tosun, Rabia Oztas Kara, Jie Li, Anastasia Allenova, Paulo Ricardo Criado   +33 more
wiley   +1 more source